Aclarion Inc. Common Stock (ACON)

FairStock Score: 53/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Buffett-and-Graham-minded investor, I start with durable earnings and a margin of safety. Aclarion does not offer either. It is a 10-employee healthcare technology company whose NOCISCAN product uses magnetic resonance spectroscopy to analyze intervertebral discs. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $25,208 and net income was -$2.7M—costs were vastly larger than sales. That pattern is not new. In FY2025, the year ended 2025-12-31, revenue was $75,730 and net income was -$7.2M; FY2024, ended 2024-12-31, revenue was $45,724 and net income was -$7.0M; FY2023, ended 2023-12-31, revenue was $75,404 and net income was -$4.9M. The Lynch category is 'none' because the company has lost money in each of the last four years. FairStock's trailing free cash flow is -$8.3M against a $6.2M market cap at the 2026-10-13 close, a -133.9% FCF yield. FairStock's P/B of 0.31 might look cheap, but ROE is -58.97%, ROCE is -37.01%, Piotroski is 3/9, and Altman Z is -0.89. Those are signs of financial fragility, not a moat. A negative P/E of -0.29 simply says there are no earnings to value. Revenue growth is not enough when losses and cash burn persist. I see a speculative technology option, not a proven business with a margin of safety.

In plain English: Aclarion is a tiny healthcare technology company that sells NOCISCAN, a scan-based test to help analyze spinal discs. The business looks weak: it has very little revenue and loses much more money than it brings in. The stock may look cheap compared with its book value, but because the company keeps losing money and burning cash, it is not clearly a bargain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer